Skip to main content
Premium Trial:

Request an Annual Quote

Sanwa Licenses VistaGen's ES Cell Assays for Diabetes Drug Development

NEW YORK (GenomeWeb News) – Japanese pharmaceutical firm Sanwa Kagaku Kenkyusho has licensed VistaGen Therapeutics’ embryonic stem cell-based assay systems for use in diabetes drug development, VistaGen said today.
Under the terms of the license agreement, Sanwa will use three of VistaGen’s customized beta-islet differentiation assay systems to identify and screen new small-molecule drug candidates to treat type 1 and type 2 diabetes.
The companies co-developed the assays under an ongoing joint research and development agreement that used VistaGen’s ES Cell technology and bioinformatics databases to identify biomolecules for cell differentiation and insulin production.
VistaGen also has the right to participate with Sanwa on future drug development programs involving joint discoveries based on VistaGen's technology in the field of diabetes.
Financial terms of the agreement were not released.

The Scan

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.